About this Research Topic
Type 1 diabetes (T1D) is a disease marked by persistent hyperglycemia due to an autoimmune destruction of the pancreatic β-cells. T1D is associated with severe short- and long-term complications and places a heavy burden on the health of the subjects and the national healthcare budget. Following the diagnosis of T1D, there is a relative period of endogenous insulin production, called the honeymoon period or the phase of partial clinical remission (PR), when clinical and biochemical interventions could alter the trajectory of T1D. Research indicates that disease-modifying therapies that prolonging the PR phase of T1D by preserving β-cell function, may reduce the severity of the long-term complications of T1D.
These interventions to preserve the β-cells of the pancreas have however had limited protection, with successful therapies showing 15-20% effect size in preserving β-cell survival in the first year of the trials, while the impact of other agents have been limited by severe side effects. Ongoing trials with newer agents, either as monotherapies or in combination are aimed at building on the effectiveness of existing agents.
Other studies in the field of disease-modification seek to determine the scope and characteristics of PR by investigating parameters such as lifestyle, clinical, and demographic factors that impact the survival of β-cells.
This Research Topic is focused on disease-modifying approaches in the study of T1D. These approaches are not limited to the PR phase but span stages I-III of the disease. Thus, the scope includes approaches that seek to (i) clarify the determinants of PR, (ii) prolong PR by various mechanisms, (iii) reduce the predisposing factors to long-term complications of T1D such as significant augmentation of time in range of glycemia.
We invite manuscripts on original research, full and mini-reviews, and systematic reviews, on content related to:
A. Disease-modifying approaches to reduce the complications of T1D
B. Mechanistic studies of disease-modifying interventions in T1D
C. Clinical applications of disease-modifying approaches to reduce the complications of T1D
D. Hypothesis and new thinking on disease-modifying approaches in T1D.
These interventions to preserve the β-cells of the pancreas have however had limited protection, with successful therapies showing 15-20% effect size in preserving β-cell survival in the first year of the trials, while the impact of other agents have been limited by severe side effects. Ongoing trials with newer agents, either as monotherapies or in combination are aimed at building on the effectiveness of existing agents.
Other studies in the field of disease-modification seek to determine the scope and characteristics of PR by investigating parameters such as lifestyle, clinical, and demographic factors that impact the survival of β-cells.
This Research Topic is focused on disease-modifying approaches in the study of T1D. These approaches are not limited to the PR phase but span stages I-III of the disease. Thus, the scope includes approaches that seek to (i) clarify the determinants of PR, (ii) prolong PR by various mechanisms, (iii) reduce the predisposing factors to long-term complications of T1D such as significant augmentation of time in range of glycemia.
We invite manuscripts on original research, full and mini-reviews, and systematic reviews, on content related to:
A. Disease-modifying approaches to reduce the complications of T1D
B. Mechanistic studies of disease-modifying interventions in T1D
C. Clinical applications of disease-modifying approaches to reduce the complications of T1D
D. Hypothesis and new thinking on disease-modifying approaches in T1D.
Keywords: Type 1 diabetes, complications, partial clinical remission, stages of type 1 diabetes, disease-modification
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
